Pfizer's Reinhart: Doesn't expect significant drop vs. Omicron covid variant
|Ralf Reinert, Vice President of its vaccine team, offers some encouraging comments on the Omicron covid variant in a Bloomberg interview, citing that he doesn’t expect a significant drop against the new strain.
He added that it could take up to two to three weeks to know if the vaccine will be effective against the omicron variant.
Meanwhile, GlaxoSmithKline Plc said its COVID-19 antibody treatment appears effective against the variant in early testing, per Bloomberg.
The drugmaker said in a statement: “Lab tests of the mutations found in the variant showed the drug is still active against the virus.”
Market implications
S&P 500 futures gain 0.50% on the day, pausing the advance amid risk-off trading in the European indices.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.